Seagen's potential breast cancer blockbuster Tukysa shows promise in colorectal cancer

Two years after its approval, Seagen’s potential blockbuster Tukysa is off to a promising start as a treatment for breast cancer. Now the Seattle-area biotech is hoping to expand its use to colorectal cancer patients.